Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Prostvac Phase III trial results in mCRPC “by early 2017″

According to a Reuters report issued early this morning, the CEO of Barvarian Nordic has stated publicly that the company expects results of Phase III trials of Prostvac VF in men with metastatic, castration-resistant prostate cancer (mCRPC) by early 2017 or perhaps earlier. … READ MORE …

Prostvac + ipilimumab shows promise in management of mCRPC

Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Metformin + BI2536 may have significant activity in mCRPC

According to an new article in the Journal of Biological Chemistry, the combination of metformin with a polo-like kinase 1 (Plk1) inhibitor known currently as BI2536 appears to be able to suppress the spread of prostate cancer that resists all other available treatments. … READ MORE …

Efavirenz not effective in the treatment of mCRPC

Some time ago a group of French researchers initiated a Phase II trial of efavirenz (Sustiva®) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Low-dose diethystilbestrol in treatment of men with CRPC

It has been a long time since we saw any truly new data on the efficacy and safety of a very old form of hormonal therapy (diethylstilbestrol or DES) in the treatment of advanced prostate cancer. … READ MORE …

Guidelines and the current treatment of mCRPC

The December 1 issue of The ASCO Post contains two articles that will be of interest to many patients with progressive disease and their family members. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,254 other followers